GYY4137

Name: GYY4137
Brand: MedChemExpress
SKU: HY-107632
Rating: 5.0 (8 reviews)

Cat. No.: HY-107632 Purity: 98.08%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

GY4137 is a sustained-release H2S donor possessing vasodilatory, antihypertensive, and anti-inflammatory activities. GY4137 can inhibit cell growth, induce apoptosis, and cause cell cycle arrest by blocking the STAT3 pathway, demonstrating potent anticancer activity.

For research use only. We do not sell to patients.

CAS No. : 106740-09-4

Size	Stock	Quantity
Free Sample (0.1 - 0.2 mg)	Apply Now
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 8 publication(s) in Google Scholar

Other Forms of GYY4137:

GYY4137 (GMP) Get quote
GYY4137 (Standard) Get quote

8 Publications Citing Use of MCE GYY4137

In Vivo Efficacy Study

Cell Proliferation/Viability Assay

: GYY4137 purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2024 Jan 12;22(1):33. [Abstract]; The number of TUNEL-positive neurons was notably increased after SCIRI, which was significantly decreased by GYY4137 treatment (50 mg/kg; IP; 30 min before the onset of spinal cord reperfusion; Single dose).

: GYY4137 purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2024 Jan 12;22(1):33. [Abstract]; The Western blotting results demonstrated that expression of the p-MLKL, p-RIP1, and p-RIP3 in the SCIRI group were higher than those in the sham group, and the p-MLKL/MLKL, p-RIP1/RIP1, and p-RIP3/RIP3 ratios were increased. With GYY4137 treatment (50 mg/kg; IP; 30 min before the onset of spinal cord reperfusion; Single dose), these changes were largely reversed.

: GYY4137 purchased from MedChemExpress. Usage Cited in: Molecules. 2023 Jun 14;28(12):4770.; Representative Western blots for Gpx4, FTH-1, and TF expression in MRGECs of the control, 100 µg/mL LPS-treated, and 100 µg/mL LPS + GYY4137 (0.2, 0.4, 0.8, or 1 mM; for 24 h) treatment groups. β-actin was used as the internal control.

: GYY4137 purchased from MedChemExpress. Usage Cited in: Molecules. 2023 Jun 14;28(12):4770.; MRGECs were incubated in 100 µg/mL LPS and 0.8 mM GYY4137 for 24 h, and this was followed by detection of cell viability with the CCK-8 assay.

: GYY4137 purchased from MedChemExpress. Usage Cited in: Molecules. 2023 Jun 14;28(12):4770.; Representative Western blots for Gpx4, FTH-1, and TF expression in the kidney tissues from mice subjected to CLP and treated with different concentrations of GYY4137 (5, 10, 25, or 50 mg/kg; IP; 30 min after CLP treatment; Single dose).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All STAT Isoform Specific Products:

View All Isoforms

STAT3 STAT5 STAT6 STAT1

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All NO Synthase Isoform Specific Products:

View All Isoforms

nNOS iNOS eNOS

View All COX Isoform Specific Products:

View All Isoforms

COX COX-1 COX-2 COX-3

View All TNF Receptor Isoform Specific Products:

View All Isoforms

TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF10B/DR5/CD262 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All Interleukin Related Isoform Specific Products:

View All Isoforms

IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[6]

Stat-3

Cellular Effect

Cell Line	Type	Value	Description	References
MCF7	IC₅₀	368.2 μM Compound: 1, GYY4137	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 4 days by crystal violet assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 4 days by crystal violet assay	[PMID: 26147240]
MCF7	IC₅₀	> 500 μM Compound: 1, GYY4137	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 26147240]
MDA-MB-231	IC₅₀	239.6 μM Compound: 1, GYY4137	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay	[PMID: 26147240]
PC-3	IC₅₀	> 200 μM Compound: 1, GYY4137	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 26147240]
SK-OV-3	IC₅₀	332 μM Compound: 1, GYY4137	Cytotoxicity against human SKOV3 cells assessed as inhibition of cell proliferation after 4 days by crystal violet assay Cytotoxicity against human SKOV3 cells assessed as inhibition of cell proliferation after 4 days by crystal violet assay	[PMID: 26147240]
WI-38	IC₅₀	1977 μM Compound: 1, GYY4137	Toxicity in human WI38 cells assessed as inhibition of cell proliferation after 4 days by crystal violet assay Toxicity in human WI38 cells assessed as inhibition of cell proliferation after 4 days by crystal violet assay	[PMID: 26147240]

In Vitro

GYY4137 (400-800 μM) causes concentration-dependent killing of seven different human cancer cell lines (HeLa, HCT-116, Hep G2, HL-60, MCF-7, MV4-11 and U2OS) but did not affect survival of normal human lung fibroblasts (IMR90, WI-38)^[2].
GYY4137 (0.1-0.5 mM) decreases LPS-induced production of nitrite (NO2 ), PGE2, TNF-α and IL-6 from human synoviocytes (HFLS) and articular chondrocytes (HAC), reduces the levels and catalytic activity of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and reduced LPS-induced NF-κB activation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	HeLa, HCT-116, Hep G2, HL-60, MCF-7, MV4-11 and U2OS
Concentration:	400 or 800 µM
Incubation Time:	5 days
Result:	Significantly affected cancer cell survivability.

In Vivo

GYY4137 (100-300 mg/kg; i.p.; daily for 14 days) significantly reduces the tumor volume in both animal models, in a dose-dependent manner^[2].
In the complete Freund's adjuvant (CFA)-treated mouse, GYY4137 (50 mg/kg, i.p.) injected 1 hr prior to CFA increased knee joint swelling while an anti-inflammatory effect, as demonstrated by reduced synovial fluid myeloperoxidase (MPO) and N-acetyl-β-D-glucosaminidase (NAG) activity and decreased TNF-α, IL-1β, IL-6 and IL-8 concentration, was apparent when GYY4137 was injected 6 hrs after CFA^[3].
GYY4137 significantly inhibited tumor growth in the subcutaneous HepG2 xenograft model by inhibiting STAT3 activation and its target gene expression^[4].
GYY4137 prevents nitrative stress and α-synuclein nitration in an MPTP mouse model of parkinson’s disease^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female, severe combined immunodeficiency (SCID) mice (bearing HL-60 or MV4-11 cells)^[2]
Dosage:	100, 200 and 300 mg/kg
Administration:	I.p.; daily for 14 days
Result:	Reduced tumor volume by 52.5% and 55.3% in HL-60 and MV4–11 injected animals.

Molecular Weight

376.47

Formula

C₁₅H₂₅N₂O₃PS₂

CAS No.

106740-09-4

Appearance

Solid

Color

White to off-white

SMILES

SP(N1CCOCC1)(C2=CC=C(OC)C=C2)=S.N3CCOCC3

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (265.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 19.23 mg/mL (51.08 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6563 mL	13.2813 mL	26.5625 mL
5 mM	0.5313 mL	2.6563 mL	5.3125 mL
10 mM	0.2656 mL	1.3281 mL	2.6563 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 50 mg/mL (132.81 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 98.08%

Select Batch:

Data Sheet (279 KB) SDS (393 KB)

COA (246 KB) HNMR (141 KB) CNMR (141 KB) RP-HPLC (168 KB) LCMS (391 KB)

Handling Instructions (2659 KB)

References

[1]. Li L, et al. Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. Circulation. 2008;117(18):2351-2360. [Content Brief]

[2]. Lee ZW, et al. The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One. 2011;6(6):e21077. [Content Brief]

[3]. Li L, et al. The complex effects of the slow-releasing hydrogen sulfide donor GYY4137 in a model of acute joint inflammation and in human cartilage cells. J Cell Mol Med. 2013;17(3):365-376. [Content Brief]

[4]. Lu S, Gao Y, et al. GYY4137, a hydrogen sulfide (H₂S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway. Int J Oncol. 2014;44(4):1259-1267. [Content Brief]

[5]. Hou X, et al. GYY4137, an H2S Slow-Releasing Donor, Prevents Nitrative Stress and α-Synuclein Nitration in an MPTP Mouse Model of Parkinson's Disease. Front Pharmacol. 2017;8:741. Published 2017 Oct 30. [Content Brief]

[6]. Lu S, et al. GYY4137, a hydrogen sulfide (H2S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway[J]. International journal of oncology, 2014, 44(4): 1259-1267. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	2.6563 mL	13.2813 mL	26.5625 mL	66.4064 mL
	5 mM	0.5313 mL	2.6563 mL	5.3125 mL	13.2813 mL
	10 mM	0.2656 mL	1.3281 mL	2.6563 mL	6.6406 mL
	15 mM	0.1771 mL	0.8854 mL	1.7708 mL	4.4271 mL
	20 mM	0.1328 mL	0.6641 mL	1.3281 mL	3.3203 mL
	25 mM	0.1063 mL	0.5313 mL	1.0625 mL	2.6563 mL
	30 mM	0.0885 mL	0.4427 mL	0.8854 mL	2.2135 mL
	40 mM	0.0664 mL	0.3320 mL	0.6641 mL	1.6602 mL
	50 mM	0.0531 mL	0.2656 mL	0.5313 mL	1.3281 mL
DMSO	60 mM	0.0443 mL	0.2214 mL	0.4427 mL	1.1068 mL
	80 mM	0.0332 mL	0.1660 mL	0.3320 mL	0.8301 mL
	100 mM	0.0266 mL	0.1328 mL	0.2656 mL	0.6641 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

GYY4137 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

GYY4137

Customer Review

Other Forms of GYY4137:

GYY4137 Related Antibodies

8 Publications Citing Use of MCE GYY4137

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All STAT Isoform Specific Products:

View All NF-κB Isoform Specific Products:

View All NO Synthase Isoform Specific Products:

View All COX Isoform Specific Products:

View All TNF Receptor Isoform Specific Products:

View All Interleukin Related Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

GYY4137 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

GYY4137 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report